News | October 18, 2011

ESC Helps Address 40 Percent Mortality in Chinese Cardiac Patients

October 18, 2011 — At more than 40 percent, the mortality rate due to cardiovascular disease (CVD) in China is amongst the highest in the world. Its population faces a catalog of CVD risk factor statistics that expose high levels of obesity, diabetes, cholesterol and blood pressure; the male population also displays a smoking habit that is proving difficult to address. To help reverse these trends, the European Society of Cardiology (ESC) delivered an educational program at the 22nd Great Wall International Congress of Cardiology.

The ESC was invited for the second time by its affiliate, the Chinese Society of Cardiology (CSC), to co-host a special symposium during the congress, which ran Oct. 15-16 in Beijing.

International collaboration is a key objective of the ESC’s Global Scientific Activities (GSA) committee, which oversaw the ESC participation. A senior faculty from the society presented a series of practical case discussions jointly chaired with the CSC.

ESC’s educational program at the congress was a dedicated event providing an overview of its recent meetings and an insight into new and updated ESC Clinical Practice Guidelines. The program summarized the role of angiotensin converting enzyme (ACE) inhibitors as the cornerstone of CVD management and considered treatment strategies for a range of conditions. These include atrial fibrillation, valvular heart disease, and non-ST segment elevation myocardial infarction heart attack (STEMI).

The ESC was represented by its president, professor Michel Komajda, along with members of the ESC board, and a number of eminent cardiologists, including authors of its most recent Clinical Practice Guidelines. 

“We are very proud to be part of this joint initiative that will further strengthen the links between China and the ESC,” says Komajda. “This will be our second visit to the Great Wall International Congress of Cardiology, and we hope that the interactive program we are delivering with our Chinese colleagues will lead to in-depth discussions around the important medical issues that we meet in daily practice.”

Relevant risk factor statistics of the adult population in China highlight the scale of the challenge:

  • CVD mortality rates are more than double the typical European value
  • Obesity levels have increased from 21 percent in 2002 to 36 percent in 2010
  • More than 30 percent of the population have high blood pressure and cholesterol
  • Around 50 percent of males are regular smokers

The Chinese Society of Cardiology enjoys excellent relations with the ESC. It hosted a joint scientific session at the 2011 ESC annual congress in Paris and also took a stand in the exhibition to promote its activities.

 Hu Dayi, M.D., is a member of the organizing committee of the Great Wall International Congress of Cardiology, now the largest cardiology congress in the Asia Pacific region. 

“This event has successfully united the various cardiology bodies in China,” he says. “These include the Chinese Society of Cardiology along with the Asia Pacific Heart Association (APHA), the Chinese College of Cardiovascular Physicians (CCCP), and the Chinese Heart Rhythm Society (CHRS). It is a platform for global collaboration, and we plan to extend our cooperation with the ESC in areas such as clinical research, guideline promotion, and training.”

The ESC’s GSA Committee was established to share ESC science and knowledge outside of Europe, build closer ties with international cardiology organizations and extend the ESC mission beyond its traditional borders. 

For more information: www.escardio.org

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init